AMPH (Amphastar Pharmaceuticals Inc) Net Profit

Corporate emblem and logo of amphastar.com (AMPH)

The price trend for Amphastar Pharmaceuticals (AMPH) reflects profit dynamics, which currently stand at 0.08. The firm's stable image relies on the flawless trust clinics place in the delivery of life-saving medications. The business dominates the high-tech inhalation segment, creating barriers for cheap generics through complex certification. However, final returns remain susceptible to patent disputes and FDA verification timelines.

AMPH (Amphastar Pharmaceuticals, Inc.) Company Net Income history from 07/04/2022 to 10/31/2026

Financial and market metric breakdowns for Amphastar Pharmaceuticals, Inc. (AMPH)

- price and consensus price forecast:
Stock Quotes Amphastar Corp|AMPH - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Amphastar Corp|AMPH - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Amphastar Pharmaceuticals|AMPH - Company Book Value|Market-to-Book Ratio amphastar.com|AMPH - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Amphastar Pharmaceuticals|AMPH - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Amphastar Pharmaceuticals Inc|AMPH - Company Aggregate Debts|Debts to Book Value Amphastar Corp|AMPH - Company Long-Term Debt|Company Short-Term Loans and Borrowings Amphastar Pharmaceuticals|Quick Ratio amphastar.com
- net income and valuation multiples indicators:
AMPH - Company Net Income
Fundamental valuation:AMPH Amphastar Corp
Flagship merchandise of Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals (AMPH) is developing a complex ecosystem of injectable and inhalable products characterized by high technological barriers. The profit value dynamics reflect the daily net financial result, excluding temporary reporting gaps. This metric measures real business efficiency amid a shifting macroeconomic environment. The steady growth of the curve confirms the resilience of its defense against generics. Purchasing the asset at local peaks on the chart carries the risk of overpayment.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Pacira Corp PCRX|Company Net Income ARS Pharmaceuticals (SPRY)|TBPH (theravance.com) - Final Profit|Net Profit AQST (Aquestive Therapeutics, Inc.)|Net Profit scPharmaceuticals, Inc. SCPH|TECX - Company Net Income|Tonix Pharmaceuticals Holding (TNXP) - Net Income|sxtchina.com (SXTC) - Company Net Income|Profit After Tax EPRX (Eupraxia Pharmaceuticals Inc.)|BHST (BioHarvest Sciences Inc.) - Net Profit|EXOZ: Final Profit|Net Profit ORMP|Net Profit enterabio.com (ENTX)|Company Net Income MindWalk Holdings HYFT|Net Financial Result abvcpharma.com (ABVC)|CPIX: Net Income|Quantum BioPharma Ltd. - Profit After Payment of Taxes|FGEN: Net Profit|Telomir Pharmaceuticals Corp (TELO) - Net Profit|Company Net Income Rani Therapeutics Holdings|SNYR: Final Profit|Net Income RLYB (Rallybio Corporation)|LEXX (lexariabioscience.com) - Final Profit|Company Net Income Pulmatrix Corp PULM|PTHL (Pheton Holdings Limited) - Profit After Tax|Aptorum - Net Profit|Final Profit LYRA (lyratherapeutics.com)|IBO: Net Profit|TNF Pharmaceuticals, Inc. (TNFA) - Net Profit|Company Net Income cbdMD Inc.|PRFX: Final Profit|Company Net Income Altamira Therapeutics (CYTO)|Net Income lipella.com LIPO|Net Profit OPTN (OptiNose)|Net Profit Pieris Pharmaceuticals Inc PIRS|Procaps Group SA - Net Profit|Petros Pharma (PTPI) - Net Income|QLI: Net Profit|Company Net Income acelyrin.com (SLRN)|Net Income TFFP